Ranpirnase: Difference between revisions
Gerald Chi- (talk | contribs) No edit summary |
Gerald Chi- (talk | contribs) No edit summary |
||
| Line 1: | Line 1: | ||
{{Infobox | {{Infobox | ||
| Name = Ranpirnase | | Name = Ranpirnase | ||
| image = 2I5S.png | | image = 2I5S.png | ||
| Line 26: | Line 26: | ||
| GenLoc_end = | | GenLoc_end = | ||
}} | }} | ||
__NOTOC__ | |||
{{CMG}} | |||
==Overview== | |||
'''Ranpirnase''' is a [[ribonuclease]] [[enzyme]] found in the [[oocytes]] of the [[Northern Leopard Frog]] (''Rana pipiens''). Ranpirnase is a member of the [[pancreatic ribonuclease]] (RNase A) protein superfamily and degrades [[RNA]] [[substrate (chemistry)|substrates]] with a [[RNA sequence|sequence]] preference for [[uracil]] and [[guanine]] [[nucleotide]]s. Along with [[amphinase]], another leopard frog ribonuclease, ranpirnase has been studied as a potential [[cancer]] treatment due to its unusual mechanism of [[cytotoxicity]] tested against [[tumor]] cells.<ref name="ardelt">{{cite pmid|18673287}}</ref> | '''Ranpirnase''' is a [[ribonuclease]] [[enzyme]] found in the [[oocytes]] of the [[Northern Leopard Frog]] (''Rana pipiens''). Ranpirnase is a member of the [[pancreatic ribonuclease]] (RNase A) protein superfamily and degrades [[RNA]] [[substrate (chemistry)|substrates]] with a [[RNA sequence|sequence]] preference for [[uracil]] and [[guanine]] [[nucleotide]]s. Along with [[amphinase]], another leopard frog ribonuclease, ranpirnase has been studied as a potential [[cancer]] treatment due to its unusual mechanism of [[cytotoxicity]] tested against [[tumor]] cells.<ref name="ardelt">{{cite pmid|18673287}}</ref> | ||
Revision as of 12:12, 24 February 2015
| 2I5S.png Crystallographic structure of ranpirnase in complex with RNA.[1] |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Ranpirnase is a ribonuclease enzyme found in the oocytes of the Northern Leopard Frog (Rana pipiens). Ranpirnase is a member of the pancreatic ribonuclease (RNase A) protein superfamily and degrades RNA substrates with a sequence preference for uracil and guanine nucleotides. Along with amphinase, another leopard frog ribonuclease, ranpirnase has been studied as a potential cancer treatment due to its unusual mechanism of cytotoxicity tested against tumor cells.[2]
Ranpirnase was originally discovered by scientists at TamirBio, a biotechnology company (formerly Alfacell Corporation), where it was tested in clinical trials under the brand name Onconase. The mechanism of action of ranpirnase tumor-selective cytotoxicity has been attributed to the RNA interference pathway, potentially through cleaving siRNA molecules;[3] to cleavage of transfer RNA;[2] and to interference with the NF-κB pathway.[4] Despite early indications of promise as a mesothelioma treatment,[5][6][7] and an orphan drug status designation from the United States Food and Drug Administration in 2007,[8] the Phase III clinical trial for this indication did not demonstrate statistical significance against primary endpoints.[9]
References
- ↑ PMID 18001769 (PMID 18001769)
Citation will be completed automatically in a few minutes. Jump the queue or expand by hand - ↑ 2.0 2.1 PMID 18673287 (PMID 18673287)
Citation will be completed automatically in a few minutes. Jump the queue or expand by hand - ↑ PMID 18927512 (PMID 18927512)
Citation will be completed automatically in a few minutes. Jump the queue or expand by hand - ↑ PMID 21901170 (PMID 21901170)
Citation will be completed automatically in a few minutes. Jump the queue or expand by hand - ↑ PMID
16305992 (PMID 16305992)
Citation will be completed automatically in a few minutes. Jump the queue or expand by hand - ↑ PMID 11773179 (PMID 11773179)
Citation will be completed automatically in a few minutes. Jump the queue or expand by hand - ↑ PMID 12860938 (PMID 12860938)
Citation will be completed automatically in a few minutes. Jump the queue or expand by hand - ↑ Waknine, Yael. "New FDA Orphan Drugs: Gestiva, Onconase, Aerosolized Ciprofloxacin". Medscape. Retrieved 2 February 2015.
- ↑ "Alfacell Annual Report 2009" (PDF). Retrieved 2 February 2015.